Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model
Biomolecules · 2023
DOI: 10.3390/biom13091309 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Md Rakibul Islam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 7960…. Hauptthemen laut MEDLINE: Alendronate, Polyethylene Glycols, Melanoma, Experimental. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Texas Tech University Health Sciences Center (TTUHSC) Office of Research, Cancer Prevention Research Institute of Texas Core.
Abstract (Originalsprache)
While tumor-associated macrophages (TAM) have pro-tumoral activity, the ablation of macrophages in cancer may be undesirable since they also have anti-tumoral functions, including T cell priming and activation against tumor antigens. Alendronate is a potent amino-bisphosphonate that modulates the function of macrophages in vitro, with potential as an immunotherapy if its low systemic bioavailability can be addressed. We repurposed alendronate in a non-leaky and long-circulating liposomal carrier similar to that of the clinically approved pegylated liposomal doxorubicin to facilitate rapid clinical translation. Here, we tested liposomal alendronate (PLA) as an immunotherapeutic agent for cancer in comparison with a standard of care immunotherapy, a PD-1 immune checkpoint inhibitor. We showed that the PLA induced bone marrow-derived murine non-activated macrophages and M2-macrophages to polarize towards an M1-functionality, as evidenced by gene expression, cytokine secretion, and lipidomic profiles. Free alendronate had negligible effects, indicating that liposome encapsulation is necessary for the modulation of macrophage activity. In vivo, the PLA showed significant accumulation in tumor and tumor-draining lymph nodes, sites of tumor immunosuppression that are targets of immunotherapy. The PLA remodeled the tumor microenvironment towards a less immunosuppressive milieu, as indicated by a decrease in TAM and helper T cells, and inhibited the growth of established tumors in the B16-OVA melanoma model. The improved bioavailability and the beneficial effects of PLA on macrophages suggest its potential application as immunotherapy that could synergize with T-cell-targeted therapies and chemotherapies to induce immunogenic cell death. PLA warrants further clinical development, and these clinical trials should incorporate tumor and blood biomarkers or immunophenotyping studies to verify the anti-immunosuppressive effect of PLA in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA.
- Nano-Oncology Research Center, Oncology Institute, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
- Department of Pharmacy Practice, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA.
- Clinical Pharmacology and Experimental Therapeutics Center, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75235, USA.
- Department of Pharmaceutical Science, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75235, USA.
- Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
ORCID-Profile: Md Rakibul Islam, Patricia Ines Back, Claire Shudde, Alberto A Gabizon
Förderung
- NCI NIH HHS
- Texas Tech University Health Sciences Center (TTUHSC) Office of Research
- Cancer Prevention Research Institute of Texas Core
- National Institute of Health
Zitieren
APA
Islam, M. R., Patel, J., Back, P. I., Shmeeda, H., Kallem, R. R., Shudde, C., Markiewski, M., Putnam, W. C., Gabizon, A. A., & La-Beck, N. M. (2023). Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model. Biomolecules. https://doi.org/10.3390/biom13091309
Vancouver
Islam MR, Patel J, Back PI, Shmeeda H, Kallem RR, Shudde C, et al. Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model. Biomolecules. 2023. doi:10.3390/biom13091309
BibTeX
@article{Islam2023,
author = {Islam, Md Rakibul and Patel, Jalpa and Back, Patricia Ines and Shmeeda, Hilary and Kallem, Raja Reddy and Shudde, Claire and Markiewski, Maciej and Putnam, William C and Gabizon, Alberto A and La-Beck, Ninh M},
title = {Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13091309}
}
EUVIMED